United States Food and Drug Administration’s authorization of reduced exposure claims for IQOS(®): implications for regulation in Latin America

Philip Morris International has used the July 7, 2020 United States Food and Drug Administration’s (US FDA) modified risk tobacco product order for IQOS(®), which authorized certain reduced exposure marketing claims, as a corporate strategy to promote and normalize its heated tobacco products in Lat...

Descripción completa

Detalles Bibliográficos
Autores principales: Eckford, Robert, Severini, Gianella, Sebrié, Ernesto M., Muggli, Monique E., Beem, Alexandra, Rosen, Debra, Crosbie, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Organización Panamericana de la Salud 2022
Materias:
Opinion and Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553011/
https://www.ncbi.nlm.nih.gov/pubmed/36245905
http://dx.doi.org/10.26633/RPSP.2022.155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553011/
https://www.ncbi.nlm.nih.gov/pubmed/36245905
http://dx.doi.org/10.26633/RPSP.2022.155

Ejemplares similares